Vaccine market and production capabilities in the Americas

Esteban Ortiz-Prado; Estefanía Espín; Jorge Vásconez; Nathalia Rodríguez-Burneo; Nikolaos C. Kyriakidis; Andrés López-Cortés

doi:10.1186/s40794-021-00135-5

Vaccine market and production capabilities in the Americas

Journal

Tropical Diseases, Travel Medicine and Vaccines

ISSN

2055-0936

Date Issued

2021-04-13

Author(s)

Esteban Ortiz-Prado

Estefanía Espín

Jorge Vásconez

Nathalia Rodríguez-Burneo

Nikolaos C. Kyriakidis

Andrés López-Cortés

Facultad de Ciencias de la Salud Eugenio Espejo

DOI

10.1186/s40794-021-00135-5

URL

https://cris.ute.edu.ec/handle/123456789/606

Abstract

AbstractIn the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals’ distribution and production. Some Latin American countries rank in the top 20 of worldwide vaccine manufacturers, with Cuba, Brazil, México and Colombia have a self-sufficient vaccine production of 72.7%, 54,2%; 25%; and 7.7%, respectively, of the national vaccine demand. On the other hand, the rest of Latin American countries cannot satisfy their demand for vaccines, and most of their efforts are associated with the distribution within their health systems rather than in transferring technology.Based on this literature review, the results suggest an increasing growth vaccine demand, not only for their growing populations and previously established demand but also for the recently exerted pressure due to the COVID-19 pandemic.Because the American continent has a marked inequality between the hegemonic producers of vaccines, the exporters, and those that depend heavily on importing these products, this could assert technological dependence in countries with rapid population growth and jeopardize the effectiveness of the two vaccination plans.